Anton Gopka is a Managing Partner at NY-based Life Sciences venture firm ATEM Capital. Prior to ATEM he managed a $760M partnership with Domain Associates. Over the last few years Gopka had 5 of his portfolio companies listed on NASDAQ, notably Atea Pharmaceuticals, which yielded a 30x return at IPO, Marinus and Syndax. Three of his portfolio companies have been sold, including Tobira Therapeutics, which was acquired by Allergan at a record 19x premium. Before ATEM Capital, Gopka was a VP at Barclays Capital and Dresdner Kleinwort, where he advised on M&A and capital market transactions exceeding $20B. Gopka is a member of the Forbes Business Council, the Private Directors Association, and the Review Committee of the National Cancer Institute at NIH.